2023
DOI: 10.2174/1568026623666230207095253
|View full text |Cite
|
Sign up to set email alerts
|

4-Nerolidylcatechol (4-NC) and Docetaxel Synergize in Controlling Androgen- independent Prostate Cancer Cells

Abstract: Background: Effective cancer treatment still challenges medicine since the strategies employed so far are not sufficiently safe and capable of specifically eliminating tumor cells. Prostate cancer (PCa) is a highly incident malignant neoplasm, and the outcome of patients, especially those with advanced castration-resistant PCa (CRPC), depends directly on the efficacy of the therapeutic agents, such as docetaxel (DOC). background: Effective cancer treatment still challenges medicine, since the strategies empl… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
0
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 76 publications
1
0
0
Order By: Relevance
“…There have also been trials combining docetaxel with natural products to treat prostate cancer. As expected, the combination of natural products with docetaxel has been shown to have synergistic effects in the treatment of prostate cancer [14,15].…”
Section: Introductionsupporting
confidence: 68%
“…There have also been trials combining docetaxel with natural products to treat prostate cancer. As expected, the combination of natural products with docetaxel has been shown to have synergistic effects in the treatment of prostate cancer [14,15].…”
Section: Introductionsupporting
confidence: 68%